Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information‐Based Mapping Exercises Across the 42 Integrated Care Boards of England
Clinical Obesity · 2026-02 · 16 (1)
DOI: 10.1111/cob.70044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Obesity, online erschienen am 11.09.2025. Verfasst von Anne de Bray und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Metabolism and Systems Science, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptides, Anti-Obesity Agents, Overweight. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.
Abstract (Originalsprache)
Obesity medications are recommended in England with legislation necessitating their availability. However, given the number of people who meet clinically approved eligibility criteria, funding these medications and associated support services may limit efficacy at a population health level. This study aimed to assess the commissioning and availability of services and obesity medications across England. Three sets of freedom of information requests were sent to the 42 ICBs in England by Sky News Ltd, The BMJ and the study investigators of this work with questions focused on commissioning of services and medication eligibility and prescription across England. The three data sets were combined to provide a narrative description to inform further development in obesity care. The availability of services across England was partial, and when services did exist, medication access was limited by funding and more restrictive eligibility criteria beyond those approved by the National Institute of Health and Care Excellence. Subsequently, very few patients receive NHS prescriptions even in areas where funding medications are reportedly available. The capacity of services to offer comprehensive care for patients to receive obesity medications is insufficient to meet current demand. Despite legislation for the delivery of obesity medications, these treatment options are not widely available on the NHS. There is insufficient service capacity to provide comprehensive care for eligible patients seeking obesity medications as a treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Metabolism and Systems Science, University of Birmingham, Birmingham, UK.
- Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Oxford, UK.
- Sky News Ltd, London, UK.
- The British Medical Journal (BMJ), London, UK.
- Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
- Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
ORCID-Profile: Stuart W Flint, Jonathan M Hazlehurst
Förderung
- National Institute for Health and Care Research
Zitieren
APA
de Bray, A., Schnitzer, H., Mahase, E., Singh, P., Andrews, R., McGowan, B. M., Le Brocq, S., Wilding, J. P. H., Flint, S. W., & Hazlehurst, J. M. (2026). Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information‐Based Mapping Exercises Across the 42 Integrated Care Boards of England. Clinical Obesity, 16(1). https://doi.org/10.1111/cob.70044
Vancouver
de Bray A, Schnitzer H, Mahase E, Singh P, Andrews R, McGowan BM, et al. Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information‐Based Mapping Exercises Across the 42 Integrated Care Boards of England. Clinical Obesity. 2026;16(1). doi:10.1111/cob.70044
BibTeX
@article{deBray2026,
author = {de Bray, Anne and Schnitzer, Hanna and Mahase, Elisabeth and Singh, Puspha and Andrews, Rob and McGowan, Barbara M and Le Brocq, Sarah and Wilding, John P H and Flint, Stuart W and Hazlehurst, Jonathan M},
title = {Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information‐Based Mapping Exercises Across the 42 Integrated Care Boards of England},
journal = {Clinical Obesity},
year = {2026},
volume = {16},
number = {1},
doi = {10.1111/cob.70044}
}
EUVIMED